109820.KQ GeneMatrix Inc
- Market cap
- KRW 28.0B
- P/E
- -
- P/B
- 1.56x
- ROE
- 5.2%
- Dividend yield
- -
- Fundamental score
- 1.1/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 109820.KQ undervalued?
Graham numberThe Graham number of GeneMatrix Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
GeneMatrix Inc fundamental analysis
6 of 22 checks passedROE 0/2
Low return on equity (5.2%), below 10%.
ROA 1/1
Return on assets (3.4%) is above the industry median (-10.1%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share did not grow over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 1/1
Last year's EPS growth (51.1%) is above the industry median (4.8%).
Revenue Growth 0/2
Revenue shrank 1.7% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 0/2
Debt to equity cannot be calculated: debt is not reported or equity is negative.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Debt Coverage 0/1
Debt is not reported.
Interest Coverage 1/1
EBIT is 9.6x against interest expense, well covered.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 1/1
Price to book (1.6x) is below the industry median (2.4x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
GeneMatrix Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About GeneMatrix Inc
GeneMatrix Inc. develops diagnostic products for various diseases in the field of molecular diagnostics. The company offers products for hepatitis B, hepatitis C, cervical cancer, sexually transmitted infections, respiratory infections, and gastrointestinal infections; vaccines for preventing various diseases; and new natural pharmaceutical materials for health enhancement and treatment. It also provides biochemical diagnostics, such as special chemistry and general chemistr…
Full company profileGeneMatrix Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
GeneMatrix Inc annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 5.08B | 5.19B | 4.73B | 5.05B | 15.9B | 12.1B | 11.2B | 9.81B | 10.0B | 10.6B | 10.9B |
| Gross Profit | 1.93B | 1.86B | 1.76B | 1.79B | 11.3B | 5.87B | 5.15B | 4.90B | 5.81B | 6.33B | 6.77B |
| Operating Income | -4.07B | -1.76B | -3.21B | -2.23B | 2.36B | -1.23B | -1.52B | -2.55B | -1.64B | -679M | 132M |
| EBITDA | - | - | - | - | - | - | -7.48B | -172M | -3.00B | -1.17B | 1.55B |
| Net Income | -3.78B | -1.47B | -3.11B | -1.37B | 8.03B | -988M | -8.11B | -895M | -3.75B | -1.83B | 935M |
| EPS | -246 | -96 | -194 | -76 | 402 | -49 | -406 | -45 | -188 | -92 | 47 |
| Balance Sheet | |||||||||||
| Total Assets | 19.3B | 17.7B | 31.5B | 28.5B | 38.2B | 39.5B | 31.9B | 31.4B | 28.5B | 27.3B | 27.6B |
| Total Liabilities | 6.85B | 6.68B | 20.7B | 13.2B | 4.78B | 7.21B | 7.72B | 8.21B | 9.23B | 9.80B | 9.66B |
| Shareholders' Equity | 12.5B | 11.1B | 10.8B | 15.2B | 33.4B | 32.3B | 24.2B | 23.1B | 19.2B | 17.5B | 17.9B |
| Cash & Short-term Investments | 9.53B | 7.65B | 15.3B | 8.98B | 12.2B | 12.5B | 4.80B | 2.13B | 1.83B | 2.27B | 5.66B |
| Total Debt | - | - | 7.82B | 3.64B | 3.64B | - | - | - | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -373M | -1.77B | -2.74B | -2.28B | 4.51B | 3.37B | -1.02B | -2.35B | -200M | 1.29B | 1.81B |
| Capital Expenditure | 271M | 182M | 345M | 191M | 367M | 258M | 173M | 161M | 33.7M | 64.5M | 64.0M |
| Free Cash Flow | - | - | - | - | 4.14B | 3.11B | -1.20B | -2.51B | -234M | 1.23B | 1.74B |
| Ratios | |||||||||||
| ROE | -30.3% | -13.3% | -28.7% | -9.0% | 24.0% | -3.1% | -33.5% | -3.9% | -19.5% | -10.5% | 5.2% |
| ROA | -19.5% | -8.3% | -9.9% | -4.8% | 21.0% | -2.5% | -25.4% | -2.9% | -13.2% | -6.7% | 3.4% |
| Net Profit Margin | -74.4% | -28.3% | -65.6% | -27.1% | 50.5% | -8.2% | -72.3% | -9.1% | -37.4% | -17.2% | 8.6% |
| Debt to Equity | - | - | 0.72x | 0.24x | 0.11x | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
GeneMatrix Inc dividends
GeneMatrix Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1.5:1 on Jul 24, 2018.
Who owns GeneMatrix Inc
- Insiders 15.99%
- Institutions 0.29%
- Public & others 83.72%
- Shares outstanding 20.0M
- Free float 15.0M
GeneMatrix Inc company profile
- Company name
- GeneMatrix Inc
- Ticker
- 109820.KQ
- ISIN
- KR7109820001
- Exchange
- KOSDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- Korea Bio Park B-Wing, Seongnam-si, South Korea, 463-400
- Phone
- 82 3 1628 2000
- Website
- genematrix.net
About GeneMatrix Inc
GeneMatrix Inc. develops diagnostic products for various diseases in the field of molecular diagnostics. The company offers products for hepatitis B, hepatitis C, cervical cancer, sexually transmitted infections, respiratory infections, and gastrointestinal infections; vaccines for preventing various diseases; and new natural pharmaceutical materials for health enhancement and treatment. It also provides biochemical diagnostics, such as special chemistry and general chemistry, that includes semi and full auto analyer, and calibrators and controls. The company was founded in 2000 and is headquartered in Seongnam-si, South Korea.
GeneMatrix Inc management
3- Mr. Soook KimPresident & CEO · born 1960
- Sun-Pyo HongSenior Managing Director and Executive Director · born 1968
- Suk-Joon KimSenior Managing Director and Executive Director · born 1967